Analytical Data
-
基因名
OR3A4
- Application
-
别名
OR3A4P; OR3A4; OR3A5P; Putative olfactory receptor 3A4; Olfactory receptor 17-24; OR17-24; Olfactory receptor 3A5
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P47883
-
表达区间
1-348 aa
-
氨基酸序列
MDLGNSGNDSVVTKFVLLGLTETAALQPILFVIFLLAYVTTIGGTLSILAAILMETKLHS PMYFFLGNLSLPDVGCVSVTVPAMLSHFISNDRSIPYKACLSELFFFHLLAGADCFLLTI MAYDRYLAICQSLTYSSRMSWGIQQALVGMSCVFSFTNALTQTVALSPLNFCGPNVINHF YCDLPQPFQLSCSSVHLNGQLLFVAAAFMGVAPLVLITVSYAHVAAAVLRIRSAEGRKKA FSTCSSHLTVVGIFYGTGVFSYTRLGSVESSDKDKGIGILNTVISPMLNPLIYWTSLLDV GCISHCSSDAGVSPGPPVQSSLCCLQFTALLSPPPGWGGLSPLNSHGL
-
分子量
37.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The cytochrome P450 enzyme CYP3A4 plays a crucial role in drug metabolism, influencing the pharmacokinetics of numerous medications. This enzyme is responsible for the oxidative metabolism of approximately 50% of drugs currently in use, making it essential for the biotransformation process in the liver. Variability in CYP3A4 expression and activity due to genetic polymorphisms, environmental factors such as diet and co-administered drugs, or diseases can significantly affect individual responses to medications, leading to therapeutic failure or adverse drug reactions. The production of recombinant CYP3A4 proteins has emerged as a valuable tool for pharmacological research, allowing for the investigation of drug-enzyme interactions, the effects of inhibitors and inducers, and the elucidation of metabolic pathways. Characterizing the recombinant protein provides insights into its catalytic mechanisms, substrate specificity, and regulation. Furthermore, the ability to produce large quantities of purified CYP3A4 facilitates high-throughput screening assays for drug discovery, enabling the identification of new therapeutic agents and the optimization of drug formulations. With the growing focus on personalized medicine, understanding the functional characteristics of CYP3A4 through recombinant technology is critical for predicting drug responses, minimizing adverse effects, and improving overall patient care.
